Intuitive Surgical
ISRG
$345.42
-14.15%
Intuitive Surgical develops, manufactures, and markets the da Vinci robotic system for minimally invasive surgery, along with related instrumentation, accessories, and services. As the undisputed global leader in robotic-assisted surgery with over 10,000 da Vinci systems installed worldwide, the company benefits from an entrenched installed base and high switching costs. The current investor narrative centers on robust procedure volume growth driving recurring revenue, tempered by recent FDA safety concerns over its stapler and competitive threats from Medtronic's Hugo robot, though Intuitive's strong earnings beat and raised long-term growth forecast have reinforced confidence in its market dominance.…
ISRG
Intuitive Surgical
$345.42
Related headlines
ISRG 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Intuitive Surgical's 12-month outlook, with a consensus price target around $504.15 and implied upside of +46.0% versus the current price.
Average Target
$504.15
0 analysts
Implied Upside
+46.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$324 - $685
Analyst target range
Intuitive Surgical is covered by 29 analysts, with a consensus recommendation of 'Buy' (mean rating 1.94 on a 1-5 scale where 1 is Strong Buy). The average price target is $549.66, implying a substantial 59.1% upside from the current price of $345.42. The distribution leans heavily bullish, with recent ratings from Mizuho (Neutral), TD Cowen (Buy), RBC Capital (Outperform), and BofA (Buy) indicating broad institutional support. The high target of $750.00 suggests some analysts see a 117% upside, likely assuming a return to peak valuation multiples and continued procedure volume acceleration. The low target of $366.00 is just 6.0% above the current price, reflecting downside risks from regulatory headwinds (FDA stapler concerns) or competitive pressure from Medtronic's Hugo. The wide spread between low and high ($366 to $750) indicates high uncertainty about the stock's trajectory, but the average target still implies strong conviction in the company's long-term growth story. Recent upgrades and reiterations from multiple firms (TD Cowen, RBC, BofA, Barclays) in April-July 2026 suggest analysts are looking past near-term headwinds and focusing on the fundamental strength of the business.
Bulls vs Bears: ISRG Investment Factors
Intuitive Surgical presents a classic tension between a fundamentally strong business and an extremely bearish technical setup. On the bull side, the company is firing on all cylinders: revenue growth is accelerating at 23% YoY, margins are expanding (net margin 29.6%), and the balance sheet is fortress-like with near-zero debt. Analysts are overwhelmingly bullish, with a consensus Buy and an average target implying 59% upside. On the bear side, the stock has been cut in half from its 52-week high, trading at just 0.3% above its low, with severe relative underperformance (-51% vs. S&P 500 over 1 year). Valuation remains stretched at 70.8x trailing earnings, and regulatory (FDA stapler concerns) and competitive (Medtronic Hugo) risks loom. The single most important tension is whether the company's fundamental strength can overcome the technical damage and valuation concerns. If the business continues to deliver accelerating growth and margin expansion, the stock could re-rate higher; if any cracks appear—such as a procedure volume slowdown or regulatory setback—the premium valuation leaves little cushion for downside.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 22.96% YoY to $2.77B, accelerating from 21.2% in Q4 2025 and 18.8% in Q3 2025, driven by strong procedure volume growth and da Vinci system adoption.
- Expanding Profit Margins: Net margin improved to 29.6% in Q1 2026 from 27.7% in Q4 2025 and 26.2% in Q2 2025, demonstrating operating leverage as revenue scales.
- Fortress Balance Sheet: Debt-to-equity is only 0.017, current ratio is 4.87, and TTM free cash flow is $2.83B, providing ample liquidity and financial flexibility.
- Analyst Consensus Buy with 59% Upside: 29 analysts rate ISRG a Buy with an average target of $549.66, implying 59.1% upside from the current price of $345.42, reflecting strong institutional conviction.
Bearish
- Sky-High Trailing P/E of 70.8x: The trailing P/E of 70.8x is more than double the medical devices industry average of ~25x, leaving little room for error and making the stock vulnerable to multiple compression.
- Stock in Sustained Downtrend, Down 33% in 1 Year: ISRG has declined 33.1% over the past year and is trading just 0.3% above its 52-week low of $344.55, with negative momentum across all timeframes (1-month -14.1%, 3-month -26.4%).
- FDA Safety Concerns Over Stapler: In March 2026, the FDA flagged safety concerns over Intuitive's stapler, creating regulatory and reputational headwinds that could impact procedure volumes and product adoption.
- Competitive Threat from Medtronic's Hugo Robot: Medtronic received FDA approval for its Hugo surgical robot, posing a direct competitive challenge to Intuitive's near-monopoly in robotic-assisted surgery.
ISRG Technical Analysis
Intuitive Surgical is in a sustained downtrend, with the stock declining 33.1% over the past year and currently trading at $345.42, just 0.3% above its 52-week low of $344.55. The price sits at the very bottom of its 52-week range (57.2% of the high of $603.88), indicating extreme bearish sentiment and suggesting the stock is deeply oversold, though a falling knife risk remains. The 1-year price change of -33.1% versus the S&P 500's +18.4% highlights severe relative underperformance, with a relative strength of -51.4% over the period. Short-term momentum is decisively negative: the stock has fallen 14.1% in the past month and 26.4% in the past three months, accelerating from the 6-month decline of 35.4%. This divergence—where short-term losses are steeper than the 1-year decline—signals a potential capitulation phase, but no reversal pattern has yet emerged. The 1-month relative strength of -14.4% versus the S&P 500's +0.3% confirms broad-based selling pressure. The 52-week low at $344.55 serves as critical support; a breakdown below this level could trigger further downside toward the $300 psychological level. Resistance sits at the 52-week high of $603.88, a 74.8% rally from current levels. The stock's beta is not directly provided, but its max drawdown of -41.7% and extreme volatility relative to the market (evidenced by the -51.4% 1-year relative strength) imply a beta well above 1.5, meaning the stock is significantly more volatile than the S&P 500, amplifying both downside risk and potential upside in a recovery.
Beta
1.46
1.46x market volatility
Max Drawdown
-41.7%
Largest decline past year
52-Week Range
$345-$604
Price range past year
Annual Return
-33.1%
Cumulative gain past year
| Period | ISRG Return | S&P 500 |
|---|---|---|
| 1m | -14.1% | -0.5% |
| 3m | -26.4% | +4.9% |
| 6m | -35.4% | +9.7% |
| 1y | -33.1% | +18.4% |
| ytd | -38.5% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ISRG Fundamental Analysis
Revenue growth remains robust, with Q1 2026 revenue of $2.77 billion growing 22.96% year-over-year, accelerating from the 21.2% growth in Q4 2025 and 18.8% in Q3 2025. The revenue trajectory is clearly accelerating, driven by strong procedure volume growth and increased adoption of the da Vinci system. Segment data shows Instruments and Accessories contributed $1.69 billion (60.9% of total), Services $434 million (15.7%), and Systems $651 million (23.5%), highlighting the recurring revenue base from instruments and services that provides stability. Profitability is excellent: net income for Q1 2026 was $821.5 million, with a net margin of 29.6%, up from 27.7% in Q4 2025 and 26.2% in Q2 2025. Gross margin remains high at 66.1%, though slightly compressed from 68.0% in Q4 2024, likely due to product mix shifts. Operating margin improved to 30.9% from 30.2% in Q4 2025, demonstrating operating leverage as revenue scales. The balance sheet is fortress-like: debt-to-equity is a mere 0.017, and the current ratio stands at 4.87, indicating ample liquidity. Free cash flow (TTM) is $2.83 billion, translating to a FCF yield of 1.4% at the current market cap, which is low but reflects the premium valuation. ROE is 16.0%, solid for a medical device company, and the company generates sufficient cash to fund operations and share repurchases ($1.12 billion in Q1 2026) without relying on external financing.
Quarterly Revenue
$2.8B
2026-03
Revenue YoY Growth
+23.0%
YoY Comparison
Gross Margin
66.1%
Latest Quarter
Free Cash Flow
$2.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ISRG Overvalued?
Since net income is positive ($821.5 million in Q1 2026), the primary valuation metric is the P/E ratio. The trailing P/E is 70.8x, while the forward P/E is 28.8x, implying the market expects significant earnings growth in the coming year. The wide gap between trailing and forward P/E suggests the market is pricing in a sharp earnings acceleration, consistent with the company's raised guidance and strong procedure volume growth. Compared to the medical devices industry, Intuitive Surgical trades at a substantial premium. The trailing P/E of 70.8x far exceeds the industry average (typically 20-30x for mature device companies), representing a premium of over 100%. The forward P/E of 28.8x is more in line with growth peers but still above the sector median. This premium is justified by Intuitive's dominant market position, high recurring revenue, and superior margins (gross margin 66.1% vs. industry average ~55%). Historically, the stock's trailing P/E has ranged from 49x to 84x over the past five years. At 70.8x, it is near the middle of that range but above the 5-year average of ~60x. The current P/E is below the peak of 84x seen in late 2021, suggesting the market has moderated its growth expectations but still prices in a premium for quality. The PEG ratio of 3.17x indicates the stock is not cheap on a growth-adjusted basis, but given the accelerating revenue and margin expansion, the premium may be sustainable.
PE
70.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 49x~85x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
49.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Intuitive Surgical's primary financial risk is valuation compression. With a trailing P/E of 70.8x—far above the medical devices industry average of ~25x—the stock is priced for perfection. Any earnings miss or growth deceleration could trigger a sharp multiple contraction. The company has no debt (debt-to-equity 0.017) and ample liquidity (current ratio 4.87), so balance sheet risk is minimal. However, the low FCF yield of 1.4% means the stock offers little income cushion. Revenue concentration in instruments and accessories (60.9% of Q1 revenue) is a moderate risk if procedure volumes slow, but the recurring nature provides stability. Operating margin of 30.9% is strong but could face pressure from R&D spending ($361.9M in Q1) and potential litigation costs from the FDA stapler issue.
Market & Competitive Risks: The stock's extreme volatility—implied by a max drawdown of -41.7% and relative strength of -51.4% over 1 year—means it is highly sensitive to macro and sector rotation. A shift away from growth stocks or a rise in interest rates could compress multiples further. Competitive risk is real: Medtronic's Hugo robot received FDA approval, threatening Intuitive's near-monopoly. While Intuitive's installed base of 10,000+ systems creates high switching costs, new entrants could pressure pricing and market share. Regulatory risk is elevated following the FDA's safety concern over its stapler in March 2026, which could lead to product recalls, labeling changes, or reduced procedure volumes. The stock's beta is likely above 1.5, amplifying downside in market selloffs.
Worst-Case Scenario: In a severe adverse scenario, a combination of factors—FDA-mandated stapler recall, a Medtronic Hugo market share grab, and a broad growth stock selloff—could drive ISRG below its 52-week low of $344.55. The next psychological support is $300, representing a -13% decline from current levels. If the company also disappoints on earnings, the stock could test the $250 level, implying a -28% loss from the current price of $345.42. This worst-case aligns with the analyst low target of $366, which is already 6% above current, suggesting limited downside but not ruling out a deeper correction given the stock's history of 41.7% max drawdown.